Drug Profile


Alternative Names: Lodivixx; S-amlodipine nicotinate/valsartan; Valsartan/levamlodipine; Valsartan/S-amlodipine nicotinate

Latest Information Update: 10 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Antihypertensives; Branched-chain amino acids; Dihydropyridines; Nicotinic-acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 31 Mar 2013 Hanlim Pharmaceutical initiates a phase I trial in healthy volunteers in South Korea (NCT01819779)
  • 31 Dec 2012 Hanlim Pharmaceutical completes a phase I pharmacokinetics trial in healthy volunteers in South Korea (NCT01652339)
  • 31 Jul 2012 Phase-I clinical trials in Hypertension in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top